Sign up to save your podcasts
Or
Share Advancement in PTSD Treatment: Silo Pharma's Nasal Spray Device Study
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Advancement in PTSD Treatment: Silo Pharma's Nasal Spray Device Study
Silo Pharma Inc. is making strides in their PTSD treatment with a drug-device study on a microchip-enabled nasal spray system for SPC-15 in partnership with Resyca BV. The study aims to gather final device data for an FDA application, with CEO Eric Weisblum emphasizing the device's potential to bypass the blood-brain barrier for faster and safer therapeutic delivery. Additionally, the company is progressing with other SPC-15 studies, including a toxicology study and a large animal safety trial as requested by the FDA.
View all episodes
Silo Pharma Inc. is making strides in their PTSD treatment with a drug-device study on a microchip-enabled nasal spray system for SPC-15 in partnership with Resyca BV. The study aims to gather final device data for an FDA application, with CEO Eric Weisblum emphasizing the device's potential to bypass the blood-brain barrier for faster and safer therapeutic delivery. Additionally, the company is progressing with other SPC-15 studies, including a toxicology study and a large animal safety trial as requested by the FDA.